

Q1

arjo
EMPOWERING MOVEMENT

INTERIM REPORT
JANUARY–MARCH 2026

A stable first quarter – while shaping Arjo's future

January–March 2026 in brief

- Net sales amounted to SEK 2,698 M (2,863). Net sales grew organically by 3.8%.
- The gross margin was 42.6% (43.7).
- Adjusted EBITDA amounted to SEK 456 M (486).
- Adjusted operating profit amounted to SEK 190 M (208).
- Profit after financial items increased to SEK 148 M (125).
- Earnings per share before and after dilution increased to SEK 0.40 (0.34).
- Cash flow from operations rose to SEK 237 M (184), corresponding to a cash conversion of 52.7% (41.3).

"We deliver a stable first quarter with healthy demand and positive performance across several parts of the business. Underlying profitability was in line with last year, excluding the effects of currencies and tariffs. At the same time, we are intensifying our work to shape the company's future direction. This marks the start of the next phase in our development – towards a more focused and profitable Arjo."

ANDRÉAS ELGAARD
PRESIDENT AND CEO

Financial summary

SEK M	Quarter 1 2026	Quarter 1 2025	Rolling 12 months	Full-year 2025
Net sales	2,698	2,863	10,835	11,000
Gross profit	1,149	1,250	4,583	4,684
Gross margin, %	42.6	43.7	42.3	42.6
Adjusted EBITDA ¹⁾	456	486	1,892	1,922
Adjusted EBITDA margin, % ¹⁾	16.9	17.0	17.5	17.5
Adjusted EBITA ¹⁾	256	270	1,077	1,091
Adjusted EBITA margin, % ¹⁾	9.5	9.4	9.9	9.9
Operating profit (EBIT)	184	168	692	675
Adjusted operating profit (EBIT) ¹⁾	190	208	813	831
Profit after financial items	148	125	489	467
Net profit for the period	108	91	351	334
Number of shares, thousands	272,370	272,370	272,370	272,370
Earnings per share, SEK	0.40	0.34	1.29	1.23
Cash flow from operations	237	184	1,488	1,435
Cash conversion, %	52.7	41.3	82.0	79.3

1. Before exceptional items. See Alternative performance measures on page 16 and definitions on page 19.

A stable first quarter – while shaping Arjo's future

The first quarter marks a solid start to the year with healthy demand and organic sales growth of 3.8%. In the US, momentum in capital goods remained positive, with healthy demand for our patient handling solutions, including the new Maxi Move 5, which had a strong start to 2026. This helped offset a weaker season for the US rental business.

In most European countries, sales were in line with last year. The UK market remains challenging, resulting in lower sales than in the first quarter of 2025. At the same time, several emerging markets performed well and contributed positively to overall growth. India is one such example, where we see many opportunities for continued expansion going forward. During the quarter, we also supported the modernization of 36 public healthcare facilities in Limpopo, South Africa, through a major delivery of medical beds and therapeutic mattresses. Thanks to strong teamwork and close collaboration with the customer, the project was carried out efficiently, helping to enhance patient safety and comfort and improve working conditions for healthcare professionals.

Diagnostics also performed well during the quarter, as did service, which plays an important role in creating stability across the business and building long-term customer relationships.

External cost pressures impact margins

The gross margin was slightly lower than last year, mainly due to an unfavorable product mix and the effects of US tariffs and currencies. We are also starting to see the early effects of higher costs related to the situation in the Middle East, primarily related to transportation and energy. Through price adjustments, increased cost awareness, and efficiency improvements across the value chain, we are actively working to mitigate this impact.

The Group's underlying profitability was in line with last year when excluding the effects of currencies and tariffs. Our financial position remains stable, and both cash flow and cash conversion developed positively at the beginning of the year.

Building the next phase of Arjo's development – while delivering today

In an uncertain global environment, full focus is required to ensure strong day-to-day operations. At the same time, we are working in parallel and with high intensity to shape Arjo's long-term strategic direction. During the quarter, the focus has been on developing a shared and clear understanding of how Arjo needs to change for the future, and which areas are critical to strengthening both profitability and competitiveness.

There is strong engagement and a clear willingness to change across the organization. While we are still in the analysis and preparation phase, the direction is clear: Arjo will evolve into a more focused, robust and long-term value-creating company, while at the same time strengthening earnings in the near term. This will require clear priorities, consistency in execution and endurance over time.

With our important contribution to society, committed employees and strong customer relationships, we are well positioned to define a new and meaningful chapter in Arjo's journey – one that will make us even stronger going forward.



ANDRÉAS ELGAARD
PRESIDENT & CEO

Group performance

Net sales per segment

SEK M	Quarter 1 2026	Quarter 1 2025	Organic change	Rolling 12 months	Full-year 2025
Global Sales	1,544	1,576	4.4%	6,311	6,344
North America	1,040	1,175	2.2%	4,134	4,269
Diagnostics	117	116	11.7%	411	409
Eliminations	-3	-4	—	-21	-22
Total	2,698	2,863	3.8%	10,835	11,000

Net sales and results

First quarter 2026

Net sales for the quarter amounted to SEK 2,698 M (2,863), corresponding to an organic increase of 3.8%.

Sales in North America increased organically by 2.2%. The US continued to perform positively during the quarter, with continued high demand in patient handling equipment and service. The rental operations performed in line with the year-earlier quarter. Canada declined slightly compared with a very strong quarter last year.

Sales in Global Sales increased organically by 4.4%. A large order for medical beds in South Africa contributed positively to growth in the quarter, as did a solid performance in emerging markets such as India and Hong Kong. In Europe, markets including France and Italy performed well, while the negative trend in the UK continued during the quarter.

The diagnostics business delivered another positive quarter, reporting organic growth of 11.7%.

The gross margin was 42.6% (43.7). Patient handling and diagnostics made a positive contribution to the margin, but were offset by a higher share of sales in emerging markets and high sales of medical beds. In addition, gross profit was negatively impacted by the effects of US tariffs and currency effects totaling SEK 132 M, of which tariffs accounted for approximately SEK 10 M.

Operating expenses for the quarter amounted to SEK 961 M (1,010), corresponding to an organic increase of 2.8%.

Exceptional items amounted to SEK 6 M (40) for the quarter and mainly pertained to restructuring activities related to the sales organizations in Europe.

Adjusted EBITDA amounted to SEK 456 M (486) and the adjusted EBITDA margin was 16.9% (17.0).

Operating profit amounted to SEK 184 M (168), an improvement that was primarily due to lower exceptional items. Adjusted operating profit amounted to SEK 190 M (208) and profit before tax to SEK 148 M (125).

Net financial items for the quarter amounted to SEK -36 M (-43). Currency effects in net financial items amounted to SEK 10 M (3).

Currency effects

SEK M	Quarter 1 2026
Translation effect (vs 2025)	
Sales	-276
Cost of goods sold	+169
Gross profit	-107
Operating expenses	+77
Restructuring and other operating income/expenses	+1
Total translation effect, EBIT	-29
Transaction effect (vs 2025)	
Cost of goods sold	-15
Recognized remeasurement effects	
Other operating income/expenses	+3

Translation effects for the quarter amounted to SEK -29 M and transaction effects to SEK -15 M. In addition, the recognized revaluation effects of operating receivables and liabilities amounted to SEK +3 M for the quarter.

Cash flow and financial position

Cash flow from operations amounted to SEK 237 M (184) for the quarter. The quarter followed a normal seasonal pattern with a higher share of sales taking place at the end of the quarter, resulting in an increase in accounts receivable, which in turn led to negative cash flow from working capital of SEK -142 M (-180). The negative cash flow from changes in inventories was fully offset by cash flow from changes in accounts payable. Cash conversion for the quarter was 52.7% (41.3).

Net investments for the quarter amounted to SEK 135 M (215), divided between tangible assets of SEK 77 M (138) and intangible assets of SEK 57 M (77). The investments in tangible assets include investments in the rental fleet of SEK 53 M (101).

The Group's cash and cash equivalents amounted to SEK 898 M (609) and interest-bearing net debt was SEK 4,133 M (4,299). Arjo has contracted unutilized credit facilities of SEK 6,265 M (4,652) available for refinancing outstanding commercial paper. The equity/assets ratio amounted to 50.5% (51.2). Net debt/adjusted EBITDA was 2.2 (2.1).

Research and development

Arjo's gross research and development costs for the quarter amounted to SEK 68 M (80), of which SEK 35 M (39) was charged to operating profit. The gross costs correspond to 2.5% (2.8) of consolidated net sales.

Outlook 2026

Organic sales growth for 2026 is expected to be within the Group's target interval of 3-5%.

Other events during the quarter

Arjo receives new ESG ratings from EcoVadis and CDP

During the quarter, Arjo received two new ESG ratings from EcoVadis and CDP, highlighting the company's strong performance in environmental, social, and governance (ESG) areas. Arjo was awarded a Silver rating by EcoVadis, reflecting the company's efforts in environmental management, sustainable procurement, and human and labor rights. In addition, Arjo received a B rating from the Carbon Disclosure Project (CDP) for its emissions-reduction efforts, external disclosure, and governance practices within its own operations, as well as an A rating for its plan to reduce emissions across the value chain.

Table of new ESG ratings

EcoVadis: Silver
 CDP Climate: B
 CDP Supplier Engagement Assessment (SEA): A

Other information

Risk management

Customers and healthcare reimbursement systems

A considerable share of Arjo's revenue is derived from sales of products to public sector entities. A political discussion taking place in certain countries concerns whether private healthcare providers should be able to offer publicly funded healthcare services. There is a risk that authorities in countries where Arjo operates will decide to limit or completely discontinue public funding of private healthcare, which could affect the establishment of new hospitals and other healthcare facilities and their purchasing of healthcare products, such as Arjo's emergency and long-term care products. Sales of the Group's products are also dependent on various reimbursement systems in each of Arjo's markets. In many of Arjo's markets (such as the US), it is often the patient's insurance company that – within the framework of the existing political reimbursement system – funds or subsidizes products for the patient's emergency or long-term care. Some of the success in sales of Arjo's products in these markets is dependent on whether Arjo's products have been approved for reimbursement under the various reimbursement systems. Since Arjo conducts operations in many different countries and markets, the above-named risks are limited for the Group as a whole. As part of Arjo's strategy, the Group is increasingly focusing on highlighting the clinical and financial benefits of the Group's products and solutions, something that further reduces the risks described above.

Research and development

Arjo's future growth is also dependent on the continued expansion of new product segments and new product types in existing product segments, which is dependent on the Group's ability to influence, predict, identify and respond to changing customer preferences and needs. Arjo invests in research and development in order to produce and launch new products, but there is no guarantee that any new products will achieve the same degree of success as in the past. Nor is there any certainty that Arjo will succeed in predicting or identifying trends in customer preferences and needs, or that Arjo will identify them earlier than its competitors. To maximize the return on research and development efforts, the Group has a highly structured selection and planning process to ensure that the Group prioritizes correctly when making decisions about potential projects. This process includes careful analyses of the market, technological progress, circularity, product life cycle, choice of production method and selection of subsuppliers. Development activities are conducted in a structured manner and the deliveries of every project undergo a number of fixed control points. Arjo is focused on products and solutions that will lead to more efficient care, in which more patients can be treated, which is expected to drive demand from end customers and therefore market growth. Product development that leads to a broader product range is a means for increasing organic growth in the market in which Arjo operates.

Product liability and damage claims

As a medical device supplier, Arjo, like other healthcare industry players, may sometimes be subject to claims related to product liability and other damage claims. Such claims could involve large financial amounts, result in significant legal expenses and negatively affect the company's reputation and customer relationships. Arjo limits the risk of product liability and other damage claims related to its products and their use through the company's extensive quality and safety activities. A comprehensive insurance program is in place to cover any liability risks (including product liability) to which the Group is exposed.



Protecting and managing the infringement of intellectual property rights

Arjo invests significant financial amounts in research and development, and is continuously developing new products and technological solutions. To secure revenue from these investments, new products and technologies must be protected from unlawful use by competitors. If possible and appropriate, Arjo protects its intellectual property rights by registering patents, design and trademarks. The Group is also dependent upon know-how and trade secrets that cannot be protected under intellectual property law.

Clear instructions are in place within the Group for how to prevent, investigate and manage potential infringements. In addition, procedures are in place to ensure efficient maintenance of the existing portfolio of rights.

Changes related to general economic and political conditions

Arjo operates in several parts of the world and, like other companies, is affected by general global economic, financial and political conditions. Demand for Arjo's medical devices and solutions is influenced by various factors, including general macroeconomic trends. Uncertainty about future economic prospects, including political concerns, could adversely affect customers' decisions to buy Arjo's products and solutions, which would adversely affect Arjo's operations, financial position and results. Furthermore, changes in the political situation in a region or country, or political decisions affecting an industry or country, could also have a material adverse impact on sales of Arjo's products. Since Arjo operates in a large number of geographical markets, this risk is limited for the Group as a whole.

Given the size of the US market and the uncertainty regarding tariffs on import goods, the outcome may have an impact on Arjo's operations. Therefore, the company is closely monitoring developments and continuously evaluating the situation and any potential action to mitigate the effects of any tariffs.

Arjo is also monitoring developments in other parts of the world, such as the escalated conflict in the Middle East and its impact on the Strait of Hormuz, and Russia's invasion of Ukraine. Arjo has stopped all deliveries and production of equipment destined to Russia since 2022.

Risks in the value chain

Unforeseen and sudden events could cause disruptions to production or the supply chain, which could result in higher costs, delivery delays and non-delivery to Arjo's customers. This in turn could have a negative impact on the Group's earnings.

Arjo works continuously to identify and as far as possible prevent risks in the value chain, both in terms of ensuring the availability of materials in the production stage and in terms of delivery reliability to our customers. Arjo is closely monitoring numerous global conflicts to avoid any negative impact in its value chain to the greatest degree possible.

Sustainability-related risks

Arjo works actively to monitor and continuously evaluate sustainability-related risks and their impact on the Group's operations and earnings. This takes place in the form of, for example, a regular double materiality assessment, monitoring targets and commitments and by auditing various units within the company, such as the security aspects of the Group's production facilities or random testing of regulatory compliance. The double materiality assessment is carried out as part of Enterprise Risk Management (ERM). The Group has established a governance structure that involves both the company management and the Board, and works continuously on improving the company's sustainability activities and minimizing associated risks.

Authorities and supervisory bodies

The healthcare market is highly regulated in all of the countries where Arjo operates. Arjo's product range is subject to legislation, including EU Directives and implementing acts regarding medical devices, and the US Food and Drug Administration's (FDA) regulations and related quality systems requirements, which also encompass comprehensive evaluation, quality assurance and product documentation.

Arjo devotes significant efforts and resources to implementing and applying guidelines to ensure regulatory compliance. Annual audits are performed by designated accreditation bodies to ensure compliance for continued CE marking of Arjo's products and international legal requirements, including the FDA, MDSAP, EU MDR and UK MDR.

All of the Group's production facilities are also certified according to ISO 13485 (Medical devices – quality management systems) and ISO 9001 (Quality management systems) from BSI.

Financial risk management

Through its operations, Arjo is exposed to a number of financial risks. Arjo's management of financial risks is regulated by a policy established by the Board. Ultimate responsibility for managing the Group's financial risks and developing methods and policies for mitigating these risks lies with Group management and Group Finance. The Group's financial risks comprise currency risk, interest-rate risk, credit and counterparty risk, and tax risk, of which currency is the most important risk.

Risk of cyber attacks

Arjo is dependent on IT and its surrounding infrastructure and thus is exposed to the risk of cyber attacks and other forms of intrusion and data security. A defined, governing process is in place to counteract potential risks in this area, and the company works actively on risk assessments of its IT infrastructure and sensitive data as well as testing of these areas. This includes defined mitigating processes and controls, known as IT General Control (ITGC) to protect the company. The internal control environment is evaluated every year both by the company's Chief Information Security Officer (CISO) and by the external auditors. A risk assessment under the EU Network and Information Security 2 (NIS2) Directive has been introduced and is regularly carried out as part of the Group's overall enterprise risk management (ERM). Sensitivity analyses and penetration and restoration tests are performed regularly during the year to ensure sufficient security levels for systems, processes and data. All employees undergo training in IT security and such training is part of the onboarding process for new employees.

Transactions with related parties

Transactions between Arjo and companies in Getinge Group are specified in Note 10.

Forward-looking information

This report contains forward-looking information based on the current expectations of Arjo's Management Team. Although management considers the expectations presented by such forward-looking information to be reasonable, there is no guarantee that these expectations will prove correct. Consequently, actual outcomes may vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding the economy, market and competition, changes in legal and regulatory requirements, as well as other policy measures and fluctuations in exchange rates.

This interim report is unaudited.



Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Malmö, April 22, 2026

Johan Malmquist
Chairman of
the Board

Carl Bennet
Vice Chairman
of the Board

Ulrika Dellby
Board member

Eva Elmstedt
Board member

Dan Frohm
Board member

Ulf Grunander
Board member

Carola Lemne
Board member

Andreas Elgaard
President & CEO

Madeléne Carlsson
Board member
Employee representative

Kajsa Haraldsson
Board member
Employee representative

Consolidated financial statements

CONDENSED CONSOLIDATED INCOME STATEMENT

SEK M	Note	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Net sales	2	2,698	2,863	11,000
Cost of goods sold		-1,549	-1,613	-6,315
Gross profit		1,149	1,250	4,684
Selling expenses		-547	-586	-2,211
Administrative expenses		-379	-385	-1,463
Research and development costs	4	-35	-39	-140
Exceptional items	5	-6	-40	-155
Other operating income and expenses		3	-32	-40
Operating profit (EBIT)	3	184	168	675
Net financial items		-36	-43	-209
Profit after financial items		148	125	467
Taxes		-40	-34	-132
Net Profit for the period		108	91	334
Attributable to:				
Parent Company shareholders		108	91	334
Number of shares, thousands		272,370	272,370	272,370
Earnings per share, SEK ¹⁾		0.40	0.34	1.23

1. Before and after dilution. For definition, see page 19.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Net profit for the period	108	91	334
Other comprehensive income			
Items that cannot be restated in profit			
Actuarial gains/losses pertaining to defined-benefit pension plans	49	6	-2
Tax attributable to items that cannot be restated in profit	-12	21	20
Items that can later be restated in profit			
Translation differences	201	-745	-1,131
Hedges of net investments	6	98	101
Cash-flow hedges	24	2	8
Tax attributable to items that can be restated in profit	-18	27	48
Other comprehensive income for the period, net after tax	249	-592	-957
Total comprehensive income for the period	357	-500	-622
Comprehensive income attributable to:			
Parent Company shareholders	357	-500	-622

CONDENSED CONSOLIDATED BALANCE SHEET

SEK M	Note	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
Assets				
Intangible assets		7,283	7,365	7,215
Tangible assets		1,507	1,598	1,486
Tangible lease assets		1,197	1,144	1,214
Financial assets	7	857	824	739
Inventories		1,244	1,341	1,177
Accounts receivables		1,793	1,756	1,617
Current financial receivables	7	26	28	27
Other current receivables		548	519	548
Cash and cash equivalents	7	898	609	836
Assets held for sale		124	130	119
Total assets		15,477	15,312	14,977
Shareholders' equity and liabilities				
Shareholders' equity		7,814	7,838	7,457
Non-current financial liabilities	7	2,199	1,902	2,637
Non-current lease liabilities	7	842	797	858
Provisions for pensions, interest-bearing	7	35	34	34
Other provisions		294	302	285
Current financial liabilities	7	1,891	2,112	1,450
Current lease liabilities	7	411	407	408
Accounts payables		562	578	508
Other non-interest-bearing liabilities		1,431	1,342	1,339
Total shareholders' equity and liabilities		15,477	15,312	14,977

CONDENSED CHANGES IN SHAREHOLDERS' EQUITY FOR THE GROUP

SEK M	Share Capital	Reserves	Retained earnings	Total shareholders' equity ¹⁾
Opening balance at January 1, 2025	91	1,807	6,440	8,338
Net profit for the period	-	-	334	334
Other comprehensive income for the period, net after tax	-	-975	18	-957
Total comprehensive income for the period	-	-975	352	-622
Dividend	-	-	-259	-259
Closing balance at December 31, 2025	91	832	6,534	7,457
Opening balance at January 1, 2026	91	832	6,534	7,457
Net profit for the period	-	-	108	108
Other comprehensive income for the period, net after tax	-	212	37	249
Total comprehensive income for the period	-	212	145	357
Closing balance at March 31, 2026	91	1,045	6,679	7,814

1. Fully attributable to Parent Company shareholders.

CONDENSED CONSOLIDATED CASH-FLOW STATEMENT

SEK M	Note	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Operating activities				
Operating profit (EBIT)		184	168	675
Add-back of amortization, depreciation and write-down	3	265	278	1,136
Other non-cash items		9	3	-15
Expensed exceptional items ¹⁾		6	40	109
Paid exceptional items		-12	-14	-105
Financial items		-45	-51	-177
Taxes paid		-28	-60	-208
Cash flow before changes to working capital		379	364	1,415
Changes in working capital				
Inventories		-35	-54	77
Current receivables		-161	-76	13
Current liabilities		54	-50	-70
Cash flow from operations		237	184	1,435
Investing activities				
Acquired operations		-	-	-27
Net investments		-135	-215	-678
Cash flow from investing activities		-135	-215	-705
Financing activities				
Raising of loans		2,002	5,582	19,736
Repayment of financial liabilities		-1,993	-5,580	-19,687
Repayment of lease liabilities		-108	-117	-449
Change in pension assets/liabilities		-1	-2	-8
Change in interest-bearing receivables		6	9	49
Dividend		-	-	-259
Realized derivatives attributable to financing activities		-22	-109	-113
Cash flow from financing activities		-115	-217	-730
Cash flow for the period		-13	-248	0
Cash and cash equivalents at the beginning of the period		836	892	892
Translation differences		75	-35	-56
Cash and cash equivalents at the end of the period		898	609	836

1. Excluding write-down of non-current assets.

1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the applicable rules of Swedish Annual Accounts Act. The Parent Company has prepared the interim report in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Sustainability and Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities.

The accounting policies applied in the preparation of this interim report apply to all periods and are consistent with the accounting policies presented in the 2025 Annual Report, published on www.arjo.com.

No new or changed accounting standards that came into effect on January 1, 2026 had a material impact on Arjo. Arjo has decided not to apply in advance new standards, amendments or interpretations that have been published but will not come into effect until the fiscal year beginning on or after January 1, 2027.

The totals in the tables and calculations do not always add up due to rounding differences. Each subtotal corresponds with its original source, which can lead to rounding differences in the totals.

2 Segment reporting

SEK M	Quarter 1 2026						Quarter 1 2025					
	Global sales	North America	Diagnostic	Group functions	Eliminations	Arjo Group	Global sales	North America	Diagnostic	Group functions	Eliminations	Arjo Group
Product sales	752	631	109	-	-2	1,490	757	696	109	-	-4	1,558
Service incl. spare parts	369	160	7	-	-1	535	379	178	7	-	0	563
Revenue from contracts with customers	1,120	791	117	-	-3	2,025	1,136	874	116	-	-4	2,122
Rental	423	249	-	-	-	673	441	300	-	-	-	741
Total net sales	1,544	1,040	117	-	-3	2,698	1,576	1,175	116	-	-4	2,863
Operating profit/loss	230	242	29	-317	-	184	209	289	17	-347	-	168
Net financial items						-36						-43
Profit after financial items						148						125
Taxes						-40						-34
Net profit for the period						108						91

SEK M	Full-year 2025					
	Global sales	North America	Diagnostic	Group functions	Eliminations	Arjo Group
Product sales	3,120	2,554	379	-	-20	6,033
Service incl. spare parts	1,512	689	31	-	-2	2,229
Revenue from contracts with customers	4,632	3,243	409	-	-22	8,262
Rental	1,711	1,026	-	-	-	2,737
Total net sales	6,344	4,269	409	-	-22	11,000
Operating profit/loss	914	953	63	-1,255	-	675
Net financial items						-209
Profit after financial items						467
Taxes						-132
Net profit for the period						334

Arjo monitors its operations within the segments Global Sales, North America and Diagnostic. Arjo has significant central Group functions in the areas of Supply Chain (product supply, inventory, and distribution), IT, Quality, and Research and Development. Only a certain portion of Supply Chain's expenses are allocated to each segment. The remaining expenses

for the Group functions are recognized as Group expenses. The division of segments and the method of measuring the segments' results are conducted in a similar way in this interim report as the 2025 Annual Report. Assets and liabilities are not divided by segment since no such amounts are regularly reported to the chief operating decision maker.

3 Depreciation/amortization and write-down

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Intangible assets	-66	-62	-296
<i>Of which, attributable to acquisitions</i>	-17	-18	-70
Tangible assets	-91	-103	-399
Tangible lease assets	-108	-114	-441
Total	-265	-278	-1,136
<i>Of which, write-down</i>	-	0	-44

Depreciation/amortization and write-downs by function, SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Cost of goods sold	-175	-185	-722
Selling expenses	-42	-43	-170
Administrative expenses	-47	-48	-192
Research and development costs	-2	-2	-7
Exceptional items	-	0	-44
Total	-265	-278	-1,136
<i>Of which, write-down</i>	-	0	-44

4 Capitalized development costs

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Research and development costs, gross	-68	-80	-303
Capitalized development costs	33	41	163
Research and development costs, net	-35	-39	-140

5 Exceptional items

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Acquisition expenses	-	0	-2
Impairment of ERP system	-	-	-35
Restructuring and integration costs	-6	-40	-118
Total	-6	-40	-155

Exceptional items by function, SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Cost of goods sold	0	-6	-46
Selling expenses	-2	-4	-20
Administrative expenses	-2	-29	-86
Research and development costs	-2	-	-1
Other operating costs	-	0	-2
Total	-6	-40	-155

The table above presents the function under which the items would have been recognized if they had not been classified as exceptional items.

6 Financial assets and liabilities measured at fair value

	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Mar 31, 2026, SEK M			
Other current receivables, derivatives	0	-	0
Other financial assets	63	29	93
Total assets	64	29	93
Other non-interest-bearing liabilities, derivatives	4	-	4
Total liabilities	4	-	4
Mar 31, 2025, SEK M			
Other current receivables, derivatives	7	-	7
Other financial assets	128	-	128
Total assets	135	-	135
Other non-interest-bearing liabilities, derivatives	18	0	18
Total liabilities	18	0	18
Dec 31, 2025, SEK M			
Other current receivables, derivatives	4	-	4
Other financial assets	63	6	69
Total assets	67	6	73
Other non-interest-bearing liabilities, derivatives	3	-	3
Total liabilities	3	-	3

For a description of valuation techniques and inputs used in the valuation, please refer to Note 28 in the Annual Report for 2025. For other financial assets and liabilities in the Group, the reported values represent a reasonable approximation of their fair values.

7 Consolidated interest-bearing net debt

SEK M	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
Non-current financial liabilities	2,199	1,902	2,637
Non-current lease liabilities	842	797	858
Current financial liabilities	1,891	2,112	1,450
Current lease liabilities	411	407	408
Provisions for pensions	35	34	34
Interest-bearing liabilities	5,377	5,253	5,387
Less financial receivables	-76	-125	-82
Less pension assets	-270	-220	-214
Less cash and cash equivalents	-898	-609	-836
Interest-bearing net debt	4,133	4,299	4,255

8 Key figures for the Group

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Sales measures			
Net sales	2,698	2,863	11,000
Net sales growth, %	-5.8	3.8	-2.6
Organic growth in sales, %	3.8	3.4	3.4
Expense measures			
Selling expenses as a % of net sales	20.3	20.5	20.1
Administrative expenses as a % of net sales	14.1	13.5	13.3
Research and development costs gross as a % of net sales	2.5	2.8	2.8
Earnings measures			
EBITDA	449	446	1,811
EBITDA growth, %	0.9	-5.8	-8.4
Adjusted EBITDA ¹⁾	456	486	1,922
EBITA	250	230	971
Adjusted EBITA ¹⁾	256	270	1,091
Operating profit (EBIT)	184	168	675
Adjusted operating profit (EBIT) ¹⁾	190	208	831
Earnings per share, SEK	0.40	0.34	1.23
Margin measures			
Gross margin, %	42.6	43.7	42.6
EBITDA margin, %	16.7	15.6	16.5
Adjusted EBITDA margin, % ¹⁾	16.9	17.0	17.5
EBITA margin, %	9.3	8.0	8.8
Adjusted EBITA margin, % ¹⁾	9.5	9.4	9.9
Operating margin, %	6.8	5.9	6.1
Adjusted Operating margin, % ¹⁾	7.1	7.3	7.6
Cash flow and return measures			
Return on shareholders' equity, % ²⁾	4.5	5.7	4.2
Cash Conversion, %	52.7	41.3	79.3
Operating Capital	12,387	12,629	12,456
Return on operating capital, % ²⁾	6.6	7.8	6.7
Capital Structure			
Interest-bearing net debt	4,133	4,299	4,255
Interest-coverage ratio, multiple ²⁾	3.9	4.3	4.0
Net debt/equity ratio, multiple	0.5	0.5	0.6
Net debt/adjusted EBITDA, multiple ^{1, 2)}	2.2	2.1	2.2
Equity/asset ratio, %	50.5	51.2	49.8
Equity per share, SEK	28.7	28.8	27.4
Other			
Number of shares	272,369,573	272,369,573	272,369,573
Number of employees, average ²⁾	6,909	6,999	6,942

1. Before exceptional items. See Alternative performance measures on page 16 and definitions on page 19.

2. Rolling 12 months.

ALTERNATIVE PERFORMANCE MEASURES

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position, and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. The alternative performance measures should not be considered substitutes, but rather a supplement to, the financial statements prepared in

accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies. The alternative performance measures recognized below have not been calculated in accordance with IFRS but have been presented since Arjo believes that they are important in connection with investors' assessments of the Company and the Company's share.

	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Adjusted EBITDA/EBITA/EBIT SEK M			
EBITDA	449	446	1,811
Depreciation and impairment of tangible assets	-200	-216	-840
EBITA	250	230	971
Amortization and write-down of intangible assets	-66	-62	-296
Operating profit (EBIT)	184	168	675
Exceptional items ¹⁾	6	40	155
Add-back of write-down of exceptional items	-	0	-44
Adjusted EBITDA	456	486	1,922
Adjusted EBITA	256	270	1,091
Adjusted operating profit (EBIT)	190	208	831
	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Cash conversion			
Cash flow from operations, SEK M	237	184	1,435
Operating profit (EBIT), SEK M	184	168	675
Add-back of amortization and write-down of intangible assets and tangible assets, SEK M	265	278	1,136
EBITDA, SEK M	449	446	1,811
Cash conversion, %	52.7	41.3	79.3
	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
Net debt/equity ratio			
Interest-bearing net debt, SEK M	4,133	4,299	4,255
Shareholder's equity, SEK M	7,814	7,838	7,457
Net debt/equity ratio, multiple	0.5	0.5	0.6
	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Calculation of return on operating capital			
Total assets opening balance, SEK M	15,312	15,980	16,276
Total assets closing balance, SEK M	15,477	15,312	14,977
Average total assets, SEK M	15,395	15,646	15,626
Average total assets, SEK M	15,395	15,646	15,626
Excluding average cash and cash equivalents, SEK M	-754	-706	-864
Excluding average and other provisions, SEK M	-298	-308	-317
Excluding average other non-interest-bearing liabilities, SEK M	-1,956	-2,004	-1,990
Average operating capital, SEK M	12,387	12,629	12,456
Operating profit (EBIT), SEK M ²⁾	692	842	675
Add-back of exceptional items, SEK M ²⁾	121	137	155
EBIT after add-back of exceptional items, SEK M	813	980	831
Return on operation capital, %	6.6	7.8	6.7

1. Refer to Note 5 Exceptional items.

2. Rolling 12 months.

9 Financial data per quarter

SEK M	Quarter 1 2025	Quarter 2 2025	Quarter 3 2025	Quarter 4 2025	Quarter 1 2026
Net sales	2,863	2,678	2,646	2,814	2,698
Cost of goods sold	-1,613	-1,516	-1,558	-1,629	-1,549
Gross profit	1,250	1,162	1,088	1,185	1,149
Operating expenses	-1,010	-951	-925	-928	-961
Exceptional items	-40	-34	-13	-68	-6
Other operating income, operating expenses and income from participations in associated companies	-32	-3	2	-7	3
Operating profit (EBIT)	168	174	152	182	184
Net financial items	-43	-48	-41	-77	-36
Profit after financial items	125	126	111	104	148
Taxes	-34	-34	-30	-34	-40
Net Profit for the period	91	92	81	70	108
Adjusted EBITDA ¹⁾	486	475	436	526	456
Adjusted EBITDA margin, % ¹⁾	17.0	17.7	16.5	18.7	16.9

1. EBITDA before exceptional items. Refer to Note 5 Exceptional items, Alternative performance measures on page 16 and definitions on page 19.

10 Transactions with related parties

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Sales	6	9	23
Purchases of goods	-3	-4	-10
Accounts receivable	5	2	2
Accounts payable	2	1	1

Carl Bennet AB is the parent company and has controlling influence over the Arjo Group. In addition to the customary dividend to Carl Bennet AB, Arjo has conducted transactions with companies within the Getinge Group, of which Carl Bennet AB also has controlling influence. Arjo uses Getinge as a distributor in certain markets. Transactions involving the delivery of products and services between the groups are carried out on commercial terms and at a market-based pricing. Transactions with the Getinge Group are specified in the table above. Apart from the above, no other material related party transactions have taken place.

Parent Company financial statements

CONDENSED PARENT COMPANY INCOME STATEMENT

SEK M	Quarter 1 2026	Quarter 1 2025	Full-year 2025
Net sales	-	-	320
Administrative expenses	-47	-39	-393
Exceptional items ¹⁾	-	-28	-33
Other operating income and expenses	-1	0	-1
Operating loss (EBIT)	-48	-68	-107
Income from participations in Group companies	92	-	471
Net financial items ²⁾	-15	-20	-76
Profit/loss after financial items	29	-88	288
Taxes	13	18	-4
Net Profit/loss for the period	42	-70	284

1. Exceptional items refers to restructuring costs of SEK - M (-28) and acquisition expenses of SEK - M (0), and for the full year 2025 restructuring costs of (-33) and acquisition expenses of (0).
2. Net financial items contain interest income, interest expenses, other financial expenses and exchange-rate gains and losses attributable to the translation of financial receivables and liabilities in foreign currencies measured at the closing day rate.

CONDENSED PARENT COMPANY BALANCE SHEET

SEK M	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
Assets			
Intangible assets	404	367	384
Participations in Group companies	5,932	5,932	5,932
Other financial assets	75	124	62
Non-current financial receivables, Group companies	2,000	-	2,000
Current financial receivables, Group companies	-	10	-
Other current receivables, Group companies	306	177	306
Current receivables	34	29	44
Cash and cash equivalents	0	0	0
Total assets	8,751	6,639	8,727
Shareholders' equity and liabilities			
Shareholders' equity	4,625	4,488	4,583
Non-current financial liabilities	2,000	-	2,000
Provisions	3	26	7
Current financial liabilities	1,719	2,089	845
Current financial liabilities, Group companies	378	-	1,244
Other current liabilities, Group companies	2	11	14
Other non-interest-bearing liabilities	25	26	34
Total shareholders' equity and liabilities	8,751	6,639	8,727

Intangible assets comprise software. The Parent Company's commercial paper program has a framework amount of SEK 5,000 M (5,000). The total amount issued at the end of the period amounts to SEK 1,720 M (2,096). The Parent Company's MTN program has a framework amount of SEK 5,000 M (-). The total amount issued at the end of the period amounts to SEK 2,000 M (-), with a term of two to five years, and is recognized as a non-current financial liability.

Definitions

FINANCIAL TERMS

Adjusted EBIT/Operating profit

Operating profit with add-back of exceptional items.

Adjusted EBITA

EBITA with add-back of exceptional items.

Adjusted EBITA margin

Adjusted EBITA in relation to net sales.

Adjusted EBITDA

EBITDA with add-back of exceptional items.

Adjusted EBITDA margin

Adjusted EBITDA in relation to net sales.

Cash conversion

Cash flow from operations in relation to EBITDA.

Earnings per share

Profit for the period attributable to Parent Company shareholders in relation to average number of shares. The following data was used to calculate earnings per share for the period:

Profit for the period attributable to Parent Company shareholders	SEK 108 M
Number of shares, thousands	272,370
Earnings per share	SEK 0.40

EBIT

Operating profit.

EBITA

Operating profit before amortization and write-down of intangible assets.

EBITA margin

EBITA in relation to net sales.

EBITDA

Operating profit before amortization, depreciation and write-down.

EBITDA margin

EBITDA in relation to net sales.

Equity/assets ratio

Shareholders' equity in relation to total assets.

Exceptional items

Total of acquisition and restructuring costs as well as major non-recurring items.

Interest-coverage ratio

Profit after financial items plus interest expenses and add-back of exceptional items in relation to interest expenses. Calculated based on rolling twelve-month data.

Net debt/adjusted EBITDA

Average net debt in relation to rolling 12 months' adjusted EBITDA.

Net debt/equity ratio

Interest-bearing net debt in relation to shareholders' equity.

Operating capital

Average total assets less cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Operating expenses

Selling expenses, administrative expenses and research and development costs.

Operating margin

Operating profit in relation to net sales.

Organic change

A financial change adjusted for currency fluctuations, acquisitions and divestments.

Return on operating capital

Rolling 12 months' operating profit with add-back of exceptional items in relation to operating capital.

Return on shareholders' equity

Rolling 12 months' profit after tax in relation to average shareholders' equity.

MEDICAL AND OTHER TERMS

Compression therapy

Treatment technique which means that one uses outer pressure with a certain frequency and for a certain period of time to treat and prevent venous leg ulcers.

DVT (deep vein thrombosis)

Formation of a blood clot in one of the body's deep veins, often in the leg.

Ergonomics

A science concerned with designing the job to fit the worker to prevent illness and accidents.

ESG

An abbreviation that stands for environmental, social and governance, which are the non-financial factors in corporate reporting.

EU Medical Device Regulation (MDR)

Regulations created by the EU to ensure better protection for the public health and patient safety by establishing modernized and more robust EU legislation. All medical device manufacturers and distributors must comply with these regulations.

Pressure injuries

Sores that occur when blood flow to the skin is reduced by external pressure. Most common in patients with reduced mobility.

Prevention

Preventive activity/treatment.

Sequential VTE prevention

A treatment that aims to enhance the circulation of blood in the deep veins of the legs, which helps reduce deep vein thrombosis (blood clot in the deep veins of the legs).

US Food and Drug Administration (FDA)

The US authority responsible for protecting the public health by carrying out regular inspections of, among other things, medical devices.

VTE (venous thromboembolism)

The abbreviation VTE stands for venous thromboembolism – a blood clot in the veins, similar to DVT (above).

TELECONFERENCE

Fund managers, analysts and the media are invited to a teleconference on April 22 at 8:00 a.m. CEST.

A presentation will be held during the telephone conference. Watch the teleconference via the following link:
<https://arjo.events.inderes.com/q1-report-2026>

Participants who wish to ask verbal questions at the teleconference must register using the link below. Once registered, participants will receive a telephone number and ID number to use to log in to the conference. Registration link:
<https://events.inderes.com/arjo/q1-report-2026/dial-in>

Alternatively, use the following link to download the presentation:
<https://www.arjo.com/int/about-us/investors/reports--presentations/2026/>

A recording of the teleconference will be available for three years via the following link:
<https://arjo.events.inderes.com/q1-report-2026>

FINANCIAL INFORMATION

Updated information on, for example, the Arjo share and corporate governance is available on Arjo's website www.arjo.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.arjo.com.

The following financial statements will be published in 2026:



April 22, 2026	2026 Annual General Meeting
July 14, 2026	Interim report Jan-Jun 2026
October 22, 2026	Interim report Jan-Sep 2026

CONTACT

Maria Nilsson

Executive Vice President, Communication & Public Relations
 +46 734 244 515
maria.nilsson@arjo.com

Erik Roslund

Investor Relations & Corporate Communications Manager
 +46 768 996 303
erik.roslund@arjo.com

This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 22, 2026 at 7:00 a.m. CEST.

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions for patient transfers, hygiene, disinfection, diagnostics, treating leg ulcers, prevention of pressure injuries and deep vein thrombosis, and our medical beds are all designed to promote mobility, safety and dignity in all care situations. With over 7,000 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges.

Arjo AB · Corp. Reg. No. 559092-8064 · Hans Michelsengatan 10 · SE-211 20 Malmö · Sweden

www.arjo.com